PMID- 26403211
OWN - NLM
STAT- MEDLINE
DCOM- 20161227
LR  - 20211203
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 30
IP  - 4
DP  - 2016 Apr
TI  - Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: 
      a comprehensive review.
PG  - 586-94
LID - 10.1111/jdv.13356 [doi]
AB  - Tuberous sclerosis complex (TSC) is a genetic multisystem disorder associated 
      with constitutive overactivation of the mammalian target of rapamycin (mTOR) 
      pathway and characterized by development of benign tumours in various organs. 
      mTOR inhibitors have proven to be effective in the targeted therapy of certain 
      TSC-associated pathologies such as subependymal giant cell astrocytomas (SEGAs) 
      and renal angiomyolipomas (AMLs). Accumulating experimental and clinical data 
      suggest that mTOR inhibitors might have a systemic, disease-modifying influence 
      on affected individuals. This systematic review provides an analysis of available 
      clinical data concerning systemic effect of mTOR inhibitors and the influence of 
      mTOR inhibition on different manifestations of TSC in individual patients.
CI  - (c) 2015 European Academy of Dermatology and Venereology.
FAU - Sadowski, K
AU  - Sadowski K
AD  - Department of Neurology and Epileptology, The Children's Memorial Health 
      Institute, Warsaw, Poland.
FAU - Kotulska, K
AU  - Kotulska K
AD  - Department of Neurology and Epileptology, The Children's Memorial Health 
      Institute, Warsaw, Poland.
FAU - Schwartz, R A
AU  - Schwartz RA
AD  - Dermatology, Pediatrics, Medicine, and Preventive Medicine and Community Health, 
      Rutgers New Jersey Medical School, Rutgers University, Newark, NJ, USA.
AD  - Rutgers University School of Public Affairs and Administration, Newark, NJ, USA.
FAU - Jozwiak, S
AU  - Jozwiak S
AD  - Department of Neurology and Epileptology, The Children's Memorial Health 
      Institute, Warsaw, Poland.
AD  - Department of Child Neurology, Warsaw Medical University, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20150925
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Humans
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Tuberous Sclerosis/*drug therapy
EDAT- 2015/09/26 06:00
MHDA- 2016/12/28 06:00
CRDT- 2015/09/26 06:00
PHST- 2015/03/10 00:00 [received]
PHST- 2015/08/06 00:00 [accepted]
PHST- 2015/09/26 06:00 [entrez]
PHST- 2015/09/26 06:00 [pubmed]
PHST- 2016/12/28 06:00 [medline]
AID - 10.1111/jdv.13356 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2016 Apr;30(4):586-94. doi: 10.1111/jdv.13356. Epub 
      2015 Sep 25.